Tarsus Acquires iRenix Medical and IRX-101 in FDA-Aligned Phase 3 Ophthalmic Program

A late-stage ocular antiseptic program with FDA-aligned Phase 3 design now sits inside Tarsus Pharmaceuticals following its acquisition of iRenix Medical, bringing near-term regulatory activity into a retina segment that has seen no new approved antiseptic in more than four decades. For regulatory affairs leads tracking ophthalmic NDA pipelines, the transaction signals a credible submission trajectory built on existing Phase 2b/3 data.

IRX-101 is a stable aqueous chlorine dioxide solution intended to replace povidone-iodine as the pre-procedural antiseptic for intravitreal injections. In the completed RELIEF trial (n=154), the compound demonstrated statistically significant reductions on two co-primary endpoints versus povidone-iodine: approximately 50% relative reduction in post-procedural pain scores (p=0.0003) and statistically significant improvement in corneal fluorescein staining, a direct measure of corneal surface damage. Povidone-iodine remains contraindicated in patients with iodine sensitivity, a population with no current approved alternative.

The procedural context amplifies the compliance and patient-adherence dimensions. More than 11 million intravitreal injections are performed annually in the United States, predominantly for chronic retinal conditions including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion-related macular edema, and geographic atrophy. Treatment intervals can run as frequently as every four weeks, meaning cumulative antiseptic-related toxicity is a recurring variable in patient adherence and continuity of care, a factor retina practices and QA teams managing procedural protocols will need to weigh as the program advances.

Tarsus structured the transaction to align economics with future value creation, though specific financial terms were not disclosed in the announcement. The company's prior commercial experience with XDEMVY in an underserved ophthalmic indication provides an operational reference point for the IRX-101 launch pathway, should the Phase 3 program yield a positive outcome and support an NDA filing.

The Phase 3 program's FDA alignment, combined with existing Phase 2b/3 efficacy and safety data, sets the next measurable checkpoint as Phase 3 enrollment initiation and the subsequent regulatory submission timeline Tarsus discloses in forthcoming guidance.

Source: Tarsus Pharmaceuticals, Inc. via GlobeNewswire, July 8, 2026. Investor conference call held July 8, 2026, at 4:30 p.m. ET.